Research programme: anti-CD19 chimeric antigen receptor T cell therapy - CRISPR Therapeutics

Drug Profile

Research programme: anti-CD19 chimeric antigen receptor T cell therapy - CRISPR Therapeutics

Alternative Names: Allogeneic CAR T-cell therapy - CRISPR Therapeutics; CTX 101 - CRISPR Therapeutics

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CRISPR Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 19 Jun 2017 CRISPR Therapeutics has patent protection for CRISPR-Cas9 genome editing technology
  • 06 Jun 2017 CRISPR Therapeutics signs service agreement for development and manufacturing of allogeneic CAR-T therapies with MaSTherCell
  • 06 Jun 2017 Early research in Cancer in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top